Antiplatelet Therapy and Cardiovascular Diseases

This paper finds that a triglyceride-related polygenic score modifies aspirin's effects on bleeding and cardiovascular events in older adults, with different outcomes based on genetic risk profiles.

This paper uses zebrafish models to study miR-150's role in platelet function and resistance to P2Y12 inhibitors, finding that miR-150 downregulates MASTL, leading to reduced VASP phosphorylation and clopidogrel resistance in humans.

This study investigates how CYP2C19 genetic variants affect outcomes in CLTI patients taking clopidogrel post-revascularisation.

This study evaluates a pharmacogenomic-driven algorithm to guide antiplatelet therapy in Caribbean Hispanic patients post-PCI, showing reduced MACCE incidence with genotype-guided treatment.

This study examines the association between CYP2C19 polymorphisms and major adverse cardiac events after PCI in patients with ACS or SIHD, finding no significant overall association but a numerical increase in risk for ACS patients.

The paper examines the frequency of the CYP2C19*2 polymorphism in South American ACS patients and its implications for clopidogrel response.

This study investigates the impact of CYP2C19 polymorphisms on clopidogrel efficacy in Arabs, finding increased risk of recurrent cardiovascular events in carriers of CYP2C19*2 and *3 alleles.

This study finds that CYP2C19 loss-of-function variants are associated with increased risk of ischemic stroke and MI in patients on long-term clopidogrel therapy in primary care.

This study identifies six new genetic variants associated with major adverse cardiovascular events in ACS patients on dual antiplatelet therapy and develops a predictive classifier for MACE.

The paper investigates genetic polymorphisms in CYP2C19 and ITGB3 genes and their impact on clopidogrel and aspirin efficacy in cardiovascular patients post-PCI.

This study evaluates the outcomes of acute coronary syndrome patients genotyped for CYP2C19, comparing personalized antiplatelet therapy with ticagrelor and clopidogrel.